Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Vir Biotechnology Inc VIR

Vir Biotechnology, Inc. is an immunology company, which is focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions. The Company's clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). It also has several preclinical candidates in its pipeline including those targeting influenza A and B, COVID-19, respiratory syncytial virus and human metapneumovirus (RSV and MPV), and human papillomavirus (HPV). The Company's pipeline includes VIR-1949, VIR-7229, VIR-2981, VIR-8190, and HIV Cure. It also engaged in developing tobevibart, a monoclonal antibody also known as VIR-3434, and Elebsiran, an siRNA also known as VIR-2218, for the treatment and suppression of chronic HDV. Its Elebsiran is an investigational HBV-targeted siRNA that reduces HBsAg, a protein which is required for the HDV viral life cycle.
ο»Ώ

NDAQ:VIR - Post by User

Bullboard Posts
Next >>
Post by Saaaa1on May 06, 2021 8:18pm
256 Views
Post# 33149340

$iMIN making moves in Ethereum Crypto !! πŸš€πŸš€πŸš€πŸš€πŸš€

$iMIN making moves in Ethereum Crypto !! πŸš€πŸš€πŸš€πŸš€πŸš€
iMining Launches Fractional Staking to Enable Retail Investors to Participate in Ethereum 2.0's Proof-Of-Stake Mining
Vancouver, British Columbia - (Newsfile Corp. - April 20, 2021) - iMining Blockchain and Cryptocurrency Inc. (TSXV: IMIN) (the "Company" or "iMining") is excited to announce that its wholly-owned subsidiary, CanETH Staking Services Inc. ("CanETH"), has launched their Fractional Staking Pool product. "This is a huge win, allowing more people to earn returns from Ethereum, as investors can participate with as little as 1 ETH and earn returns from their investment," said Robert Eadie, President and CEO of iMining. This Fractional Staking Pool allows more retail investors to partake in Ethereum 2.0 staking, opening up the market to those looking to invest smaller amounts with CanETH's proprietary Staking Services. "CanETH's Fractional Staking Pool allows us to assist more 'everyday' investors, particularly those who aren't able to invest 32 ETH," explains Daren Tung, CEO of CanETH. "As the price of Ethereum continues to increase, it is exciting to level out the playing field, and allow more users to stake with us and benefit from the growth in Ethereum 2.0." CanETH has simplified the Fractional Staking Pool process by taking control of the complex technical aspects of the setup and management for its users and ensuring maximum uptime and returns. Participants can join the pool with a minimum of 1 ETH and may earn a return of their investment in the form of staking rewards. To date, ETH 2.0 Staking rewards have been performing at 8% along with a 404% increase in ETH in the last 6 months. To participate, investors can register at https://caneth.com/stake-with-us CanETH's validators are maintaining 99% efficiency and a 0% slashing rate as a result of their best-in-class technology. By adding infrastructure and developing the product suite, CanETH continues to give more users access, allowing them to benefit from the growth and returns in Ethereum 2.0. CanETH's Platform 2.0 is due to be released in Q2, with more upcoming and exciting song to make ETH staking easier for all investors. ON BEHALF OF THE BOARD iMining Blockchain and Cryptocurrency Inc. Signed "Robert Eadie" Robert Eadie, President & Chief Executive Officer FOR FURTHER INFORMATION, or to arrange an interview with any of our team, please contact: CanETH Press: Rinn Maximus, Publicist, CanETH Staking Services Email: media@CanETH.com iMining Corporate Offices: Robert Eadie, Chief Executive Officer and Director, iMining Email: investor@imining.com Telephone: 1-604-602-4935 ♦ Facsimile: 1-604-602-4936 CanETH Staking Services: Daren Tung, CEO, CanETH Staking Services Email: dtung@CanETH.com About iMining Blockchain and Cryptocurrency iMining is a growth oriented, TSXV listed company, focused on linking traditional capital markets with blockchain investment opportunities. Through its wholly owned subsidiary, the Company provides retail and institutional investors a safe and secure way to stake Ethereum 2.0 using proprietary and secure proof of stake methods. We are driven by our core values to operate with transparency, efficiency and sustainability as we work toward building long-term shareholder value. About CanETH Staking Services Inc. A subsidiary of iMining Blockchain and Cryptocurrency Inc., CanETH has become one of the first publicly listed Ethereum 2.0 Staking Service in North America. We offer a simplified staking solution for Ethereum 2.0, providing clients with the services to participate and retain a yield in the ETH 2.0 Proof-of-Stake movement with as little as 1 ETH and without actively validating. By incorporating a proprietary, best-in-class staking process, CanETH ensures robust security, reliability and scalability; while removing the technical complexity of deploying and managing validators. Our validators have maintained 99% efficiency and 0% slashing as a result of our extensive R&D.
Please visit www.caneth.com or email at info@caneth.com.
Bullboard Posts
Next >>